Venous malformations (VMs) are ectatic channels which arise as a result of vascular dysmorphogenesis, commonly caused by activating mutations in the endothelial tyrosine kinase receptor (TIE2)/phosphatidylinositol 3-kinase (PI3Kinase) pathway. With a prevalence of 1% in the general population, and a diverse clinical presentation depending on site, size and tissue involvement, their treatment requires a personalised and multidisciplinary approach. Larger lesions are complicated by local intravascular coagulopathy (LIC) causing haemorrhagic and/or thrombotic complications which can progress to disseminated intravascular coagulopathy (DIC).
Methods
We performed a literature review using a PubMed® search and identified 15 articles to include. References of these texts were examined to further expand the literature review.
Principle findings: Several treatment options have been explored, including compression, sclerotherapy, laser therapy, cryoablation and surgery in addition to the management of LIC with low-molecular-weight-heparin (LMWH) and other anticoagulants. Targeted molecular therapies acting on the phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway are newly emerging.
Conclusion
Despite a wealth of literature, larger, multi-centric, randomised and prospective trails are required to offer further clarification on the therapeutic management of coagulopathy control and to provide symptomatic benefit to patients with VMs. There should be efforts to provide long term follow up and to use standardised risk stratification tools and quality of life (QOL) questionnaires to aid comparison of agents and treatment protocols.
MullikenJBGlowackiJ.Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg1982;
69: 412–422.
2.
VikkulaMBoonLMMullikenJB.Molecular genetics of vascular malformations. Matrix Biol2001;
20: 327–335.
SteinerJEDroletBA.Classification of vascular anomalies: an update. Semin Intervent Radiol2017;
34: 225–232.
5.
DompmartinAAcherAThibonP, et al.
Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol2008;
144: 873–877.
6.
CasanovaDBoonL-MVikkulaM.Venous malformations: clinical characteristics and differential diagnosis. Ann Chir Plast Esthet2006;
51: 373–387.
7.
NguyenHLBonadurerGFTollefsonMM.Vascular malformations and health-related quality of life: a systematic review and meta-analysis. JAMA Dermatol2018;
154: 661–669.
8.
WassefMBleiFAdamsD, et al.; on behalf of the ISSVA Board and Scientific Committee.
Vascular anomalies classification: Recommendations from the international society for the study of vascular anomalies. Pediatrics2015;
136: e203.
9.
CohenMM.Klippel-Trenaunay syndrome. Am J Med Genet2000;
93: 171–175.
10.
BrouillardPVikkulaM.Genetic causes of vascular malformations. Hum Mol Genet2007;
16: 140–149.
11.
VikkulaMBoonLMCarrawayKL, et al.
Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell1996;
87: 1181–1190.
SobletJKangasJNätynkiM, et al.
Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J Invest Dermatol2017;
137: 207–216.
14.
WoutersVLimayeNUebelhoerM, et al.
Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet2010;
18: 414–420.
15.
JiangBHZhengJZAokiM, et al.
Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA2000;
97: 1749–1753.
16.
KimIKimHGSoJN, et al.
Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3’-Kinase/Akt signal transduction pathway. Circ Res2000;
86: 24–29.
17.
KobialkaPGrauperaM.Revisiting PI3-kinase signalling in angiogenesis. Vasc Biol2019;
1: 125–134.
18.
SamuelsYWangZBardelliA, et al.
High frequency of mutations of the PIK3CA gene in human cancers. Science2004;
304: 554.
19.
KurekKCLuksVLAyturkUM, et al.
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet2012;
90: 1108–1115.
20.
LuksVLKamitakiNViveroMP, et al.
Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr2015;
166: 1048–1054.
21.
SuriCJonesPFPatanS, et al.
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell1996;
87: 1171–1180.
22.
CastilloSDTzouanacouEZaw-ThinM, et al.
Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Sci Transl Med2016;
8: 33243.
23.
LimayeNKangasJMendolaA, et al.
Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet2015;
97: 914–921.
24.
BoonLMMullikenJBEnjolrasO, et al.
Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol2004;
140: 971–976.
25.
de VosIJVreeburgMKoekGH, et al.
Review of familial cerebral cavernous malformations and report of seven additional families. Am J Med Genet A2017;
173: 338–351.
26.
BehraveshSYakesWGuptaN, et al.
Venous malformations: clinical diagnosis and treatment. Cardiovasc Diagn Ther2016;
6: 557–569.
27.
HeinKDMDMullikenJBMDKozakewichH, et al.
Venous malformations of skeletal muscle. Plast Reconstr Surg2002;
110: 1625–1635.
28.
SamadiKSalazarGM.Role of imaging in the diagnosis of vascular malformations vascular malformations. Cardiovasc Diagn Ther2019;
9: 143–151.
29.
GoyalMCauserPAArmstrongD.Venous vascular malformations in pediatric patients: comparison of results of alcohol sclerotherapy with proposed MR imaging classification. Radiology2002;
223: 639–644.
HuLChenHYangX, et al.
Risk factors associated with pain in patients with venous malformations of the extremities. Vasc Med Lond Med2019;
24: 56–62.
32.
NätynkiMKangasJMiinalainenI, et al.
Common and specific effects of TIE2 mutations causing venous malformations. Hum Mol Genet2015;
24: 6374–6389.
33.
BinetQLambertCHermansC.Dabigatran etexilate in the treatment of localized intravascular coagulopathy associated with venous malformations. Thromb Res2018;
168: 114–120.
34.
BickRL.Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome. Ann N Y Acad Sci1981;
370: 851–854.
35.
TsukamotoETaneiTKatoT, et al.
Repeated intracranial hemorrhage after delivery induced by coagulopathy associated with multiple venous malformations. World Neurosurg2019;
128: 434–437.
36.
MazoyerEEnjolrasOBisdorffA, et al.
Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol2008;
144
37.
ZhuoKRussellSWargonO, et al.
Disseminated intravascular coagulopathy in a child with extensive venous malformations. J Paediatr Child Health2017;
53: 320–321.
38.
RheeCYSpivackMAl-MondhiryH.Subacute consumption coagulopathy – an unusual complication of angiography. Am J Med Sci1975;
269: 391–394.
39.
MasonKPNeufeldEJKarianVE, et al.
Coagulation abnormalities in pediatric and adult patients after sclerotherapy or embolization of vascular anomalies. AJR Am J Roentgenol2001;
177: 1359–1363.
40.
MazoyerEEnjolrasOLaurianC, et al.
Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol2002;
24: 243–251.
41.
KooKSHDowdCFMathesEF, et al.
MRI phenotypes of localized intravascular coagulopathy in venous malformations. Pediatr Radiol2015;
45: 1690–1695.
42.
DompmartinABallieuxFThibonP, et al.
Elevated D-dimer level in the differential diagnosis of venous malformations. Arch Dermatol2009;
145: 1239–1244.
43.
ChuteCSteinBSylviaMB, et al.
Perioperative care of the vascular anomaly patient. Semin Pediatr Surg2014;
23: 233–237.
44.
WeitzJI.Low-molecular-weight heparins. N Engl J Med1997;
337: 688–698.
45.
NguyenJTKoerperMAHessCP, et al.
Aspirin therapy in venous malformation: a retrospective cohort study of benefits, side effects, and patient experiences. Pediatr Dermatol2014;
31: 556–560.
46.
Di NisioMMiddeldorpSBüllerHR.Direct thrombin inhibitors. N Engl J Med2005;
353: 1028–1040.
47.
LauxVPerzbornEHeitmeierS, et al.
Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?Thromb Haemost2009;
102: 892–899.
48.
ArdillonLLambertCEeckhoudtS, et al.
Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations. Blood Coagul Fibrinolysis2016;
27: 216–219.
49.
YasumotoAIshiuraRNarushimaM, et al.
Successful treatment with dabigatran for consumptive coagulopathy associated with extensive vascular malformations. Blood Coagul Fibrinolysis2017;
28: 670–674.
50.
RandrianarisoaEKoppH-GBalletshoferBM, et al.
Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in KlippelTrénaunay syndrome. Blood Coagul Fibrinolysis2013;
24: 766–770.
51.
Lindhoff-LastESamamaMMOrtelTL, et al.
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit2010;
32: 673–679.
HageANChickJFBSrinivasaRN, et al.
Treatment of venous malformations: the data, where we are, and how it is done. Tech Vasc Interv Radiol2018;
21: 45–54.
54.
KimBKimKJeonP, et al.
Long-term results of ethanol sclerotherapy with or without adjunctive surgery for head and neck arteriovenous malformations. Neuroradiology2015;
57: 377–386.
55.
DompmartinABlaizotXThéronJ, et al.
Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations. Eur Radiol2011;
21: 2647–2656.
56.
van der VleutenCJKaterAWijnenMH, et al.
Effectiveness of sclerotherapy, surgery, and laser therapy in patients with venous malformations: a systematic review. Cardiovasc Intervent Radiol2014;
37: 977–989.
57.
DietzekCL.Sclerotherapy: introduction to solutions and techniques. Perspect Vasc Surg Endovasc Ther2007;
19: 317–324.
58.
YamakiTNozakiMSakuraiH, et al.
Prospective randomized efficacy of ultrasoundguided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations. J Vasc Surg2008;
47: 578–584.
59.
ZhengJWYangXJWangYA, et al.
Intralesional injection of pingyangmycin for vascular malformations in oral and maxillofacial regions: an evaluation of 297 consecutive patients. Oral Oncol2009;
45: 872–876.
60.
HelalHAMahmoudNA.Effect of foam and liquid bleomycin in the management of venous malformations in head and neck region: a comparative study. J Plast Reconstr Aesthet Surg2020;
73: 90–97.
61.
ZhangJLiH-BZhouS-Y, et al.
Comparison between absolute ethanol and bleomycin for the treatment of venous malformation in children. Exp Ther Med2013;
6: 305–309.
62.
HorbachSERLokhorstMMSaeedP, et al.
Sclerotherapy for low-flow vascular malformations of the head and neck: a systematic review of sclerosing agents. J Plast Reconstr Aesthet Surg2016;
69: 295–304.
63.
AliSMitchellSE.Outcomes of venous malformation sclerotherapy: a review of study methodology and long-term results. Semin Intervent Radiol2017;
34: 288–293.
64.
PoetkeMPhilippCMUrbanP, et al.
Interstitial laser treatment of venous malformations. Med Laser Appl2001;
16: 111–119.
65.
LuXYeKShiH, et al.
Percutaneous endovenous treatment of congenital extratruncular venous malformations with an ultrasound-guided and 810-nm diode laser. J Vasc Surg2011;
54: 139–145.
66.
CornelisFHLabrèzeCPinsolleV, et al.
Percutaneous image-guided cryoablation as second-line therapy of soft-tissue venous vascular malformations of extremities: a prospective study of safety and 6-Month efficacy. Cardiovasc Intervent Radiol2017;
40: 1358–1366.
67.
RamaswamyRSTiwariTDarcyMD, et al.
Cryoablation of low-flow vascular malformations. Diagn Interv Radiol2019;
25: 225–230.
68.
ZhuoKYRussellSWargonO, et al.
Localised intravascular coagulation complicating venous malformations in children: associations and therapeutic options. J Paediatr Child Health2017;
53: 737–741.
69.
VignotSFaivreSAguirreD, et al.
mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol2005;
16: 525–537.
70.
LaplanteMSabatiniDM.mTOR signaling in growth control and disease. Cell2012;
149: 274–293.
71.
BoscoloELimayeNHuangL, et al.
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest2015;
125: 3491–3504.
72.
SalloumRFoxCEAlvarez-AllendeCR, et al.
Response of blue rubber bleb nevus syndrome to sirolimus treatment. Pediatr Blood Cancer2016;
63: 1911–1914.
73.
AdamsDMTrenorCCHammillAM, et al.
Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics2016;
137: e20153257–e20153257.
74.
AdamsDMRicciKW.Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options. Hematol Oncol Clin North Am2019;
33: 455–470.
75.
MizunoTFukudaTEmotoC, et al.
Developmental pharmacokinetics of sirolimus: implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer2017;
64: e26470.
76.
ZoccaliC.Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant2002;
17: 50–54.
77.
ZuberJAnglicheauDElieC, et al.
Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant2008;
8: 1471–1479.
78.
Efficacy and safety of sirolimus in vascular anomalies that are refractory to standard care. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02638389 (2015, accessed 8 January 2019).
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
